5-Azacitidine has limited therapeutic activity in myelofibrosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 62 citations in OpenAlex.

1. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.Blood · 2018
   Trial
2. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.American journal of hematology · 2018
   Trial
3. Novel Therapies for Myelofibrosis.Current hematologic malignancy reports · 2017
   Review
4. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.Leukemia & lymphoma · 2017
   Article
5. New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
   Review
6. Novel therapies for myelofibrosis.Leukemia & lymphoma · 2015
   Review
7. Definition and management of ruxolitinib treatment failure in myelofibrosis.Blood cancer journal · 2014
   Review
8. Novel myelofibrosis treatment strategies: potential partners for combination therapies.Leukemia · 2014
   Review
9. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.Leukemia · 2014
   Article
10. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.Therapeutic advances in hematology · 2012
    Article
11. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.Current hematologic malignancy reports · 2012
    Review
12. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Clinical epigenetics · 2011
    Article
13. Deactylase inhibition in myeloproliferative neoplasms.Investigational new drugs · 2010
    Review
14. Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms.F1000 medicine reports · 2010
    Article
15. New drugs for the treatment of myelofibrosis.Current hematologic malignancy reports · 2010
    Review
16. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.Leukemia · 2009
    Review
17. Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Journal of cellular and molecular medicine · 2009
    Review
18. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors.Leukemia · 2009
    Article
19. SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis.Leukemia · 2009
    Article
20. Novel strategies for patients with chronic myeloproliferative disorders.Current opinion in hematology · 2009
    Review

Corrections and comments

• Comment on
  A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.2008

Authors and funding

8 authors at 4 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as